US · AKTX
Akari Therapeutics, Plc
- Sector
- Healthcare · Biotechnology
- Headquarters
- London W1G 9RT
- Website
- akaritx.com
Price · as of 2024-12-31
$5.47
Market cap 4.22K
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | $1,298.00 | ||||
| 2014 | $174.00 | ||||
| 2015 | $200.00 | ||||
| 2016 | $130.00 | ||||
| 2017 | $46.00 | ||||
| 2018 | $36.60 | ||||
| 2019 | $36.40 | ||||
| 2020 | $62.40 | ||||
| 2021 | $23.30 | ||||
| 2022 | $5.80 | ||||
| 2023 | $2.14 | ||||
| 2024 | $0.93 |
AI valuation
Our deep-learning model estimates Akari Therapeutics, Plc's (AKTX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $5.47
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AKTX | Akari Therapeutics, Plc | $5.47 | 4.22K | — | — | — | — | 0.00 | 0.00 | — | -0.03 | 0.00 | 0.00 | 0.00% | — | — | -179.92% | -230.05% | -72.08% | 0.15 | 88.70 | 0.15 | 0.14 | -0.03 | 73000.00% | — | -2361.00% | -113611.27% | -0.63 | -133.42% | 0.00% | 0.00% | 0.00% | -0.03 | -0.05 | — | -8.66 |
| CDT | CDT Equity Inc. | $0.69 | 936.98K | — | +2,355% | +4,622% | — | 0.11 | 0.02 | 0.01 | 3.22 | — | -0.15 | 37.98% | 11.63% | 8.75% | 37.77% | 28.00% | 13.64% | 1.09 | -6.81 | 1.93 | 1.22 | 3.14 | -12879.00% | — | -234691.00% | 845.61% | 0.51 | 19.40% | 30.80% | 3.40% | 30.80% | 3.22 | 4.65 | 0.37 | 1.88 |
| DRMA | Dermata Therapeutics, Inc… | $1.20 | 817.87K | — | — | — | — | -0.15 | 1.19 | — | 0.11 | — | 1.19 | 0.00% | — | — | -310.44% | 932.57% | -213.46% | 0.00 | — | 1.79 | 1.60 | 0.26 | -7991.00% | — | 7418.00% | -602.98% | -5.66 | 831.94% | 0.00% | 0.00% | 0.04% | 0.10 | 0.12 | — | -36.61 |
| MSPR | MSP Recovery, Inc. | $0.04 | 537.2K | +14,182% | +17,977% | — | — | -0.01 | 0.14 | 0.76 | -1.22 | -0.01 | -0.01 | 47.36% | -6982.79% | -1975.45% | -834.83% | -139.81% | -61.30% | 7.90 | -3.03 | 0.01 | 0.01 | -1.20 | 12779.00% | 13685.00% | -6014.00% | -119.26% | -0.01 | -1.83% | 0.00% | 0.00% | 0.00% | -0.62 | -47.84 | 43.63 | -3.28 |
| PBM | Psyence Biomedical Ltd. | $2.54 | 48.31K | — | — | — | — | 121.05 | 18.22 | — | 113.47 | — | 18.22 | 0.00% | — | — | -47.61% | 1045.66% | 23.95% | 0.00 | -395.15 | 11.04 | 10.55 | -5.98 | -12268.00% | — | 2687.00% | -3.06% | -6.28 | 1068.81% | 0.00% | 0.00% | 12.94% | -31.76 | -31.07 | — | 112.16 |
| PPBT | Purple Biotech Ltd. | $0.44 | 6.05K | +36,731% | — | — | — | -9.98 | 2.21 | — | -9.12 | -0.37 | 14.48 | 0.00% | — | — | -21.71% | -50.41% | -17.90% | 0.01 | -24.62 | 2.23 | 2.21 | 1.02 | 266250.00% | -10000.00% | -2791.00% | -19.77% | -3.60 | -65.81% | 0.00% | 0.00% | 0.00% | -5.84 | -4.48 | — | 4.27 |
| REVB | Revelation Biosciences, I… | $1.32 | 1.95M | — | — | — | — | 0.00 | 0.00 | — | 0.67 | — | 0.00 | 0.00% | — | — | -201.08% | 1657.76% | -153.82% | 0.08 | — | 5.41 | 5.36 | 0.67 | -7268.00% | — | 4498931.00% | -103262.37% | -4.14 | 1511.33% | 74316.81% | -66.80% | 198525.74% | 1.10 | 1.20 | — | -7.64 |
About Akari Therapeutics, Plc
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
- CEO
- Abizer Gaslightwala
- Employees
- 8
- Beta
- 0.31
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $5.47) − 1 = — (DCF, example).